Medical representatives are too difficult, will usher in a major rectification!

"Pharmaceutical Network Industry Dynamics" recently, "correcting the pharmaceutical purchase and sale of the field and medical services in the field of the 22nd joint inter-ministerial meeting" held in Beijing.
meeting, the whole supervision of pharmaceutical supplies, regulate medical practice behavior, combat fraud insurance, rectify the operation order of the industry and other work is summarized and deployed.
, the focus is on the 2020 anti-wind work to continue to crack down on fraud to defraud health insurance funds, consolidate the effectiveness of the drug circulation field, and resolutely clean up the industry chaos.
, industry insiders believe that in 2020 pharmaceutical representatives will usher in a major overhaul, which is expected to accelerate the re-establishment of the pharmaceutical representative industry, so that it returns to the academic standard.
, in fact, the initial function of the medical representative was to continue foreign practice by introducing doctors to the efficacy of the drug, how to use it, and to collect and respond to adverse reactions in a timely manner.
But with the emergence of a large number of pharmaceutical companies in China, countless good and bad drugs are brought to market, fierce competition so that drug companies focus on the doctor's hands of the "prescription list", pharmaceutical representatives gradually become "drug sales representatives."
in order to sell drugs, pharmaceutical representatives "well-serviced", in the fierce competition gradually breed more and more commercial bribery, but also led to inflated drug prices, excessive medical treatment and many other problems.
, however, in the new situation of the pharmaceutical industry, in order to solve the above-mentioned problems and promote the return of pharmaceutical representatives to the academic standard, in recent years, the state has also begun to introduce policies to regulate pharmaceutical representatives.
For example, in 2017, the State issued the Opinions on Deepening the Reform of the Review and Approval System to Encourage Drug Medical Device Innovation, which clearly states that the academic promotion of pharmaceuticals should be regulated, that pharmaceutical representatives are responsible for the academic promotion of pharmaceuticals, and that pharmaceutical representatives are not sales personnel and should not undertake the task of drug sales.
same year, the opinions issued on further reforming and improving the production and circulation of pharmaceutical products also made it clear that the drug regulatory authorities should strengthen the management of pharmaceutical representatives, who should not undertake the task of drug sales.
June 2020, the General Department of the State Drug Administration issued the Measures for the Administration of the Filing of Pharmaceutical Representatives (Trial) (Draft for Comments) and solicited opinions publicly.
"Draft for Comments" also clearly states that pharmaceutical representatives may not undertake the task of drug sales, and may not carry out academic promotion activities in medical institutions without filing.
, with marketing compliance and anti-commercial bribery of medicines becoming the focus of attention in recent years, many hospitals have also introduced relevant regulations, in strict restrictions on the activities of pharmaceutical representatives.
Such as Shanghai Hongkou District is a second-level general hospital Jiangwan Hospital on the notice of the varieties before May 31 signed with the hospital three copies of the "commitment to integrity and self-discipline", and at the same time provide "one inch, two inches of photos each and a copy of the document" for the medical representative for the record.
, Guangxi, Shanghai, Tianjin, Beijing and other places have also issued regulatory documents for pharmaceutical representatives.
In short, from the increasing, as well as more and more detailed rules, it is not difficult to see that the country's determination to return pharmaceutical representatives to the academic standard is very firm, although in practice I am afraid there is still difficulty, but the return of pharmaceutical representatives to the academic standard has become an industry trend, and medical reform is still in-depth, medical representatives need to accelerate from "relationship" and "transaction" to "technical" transformation.
.